CGT Catapult data shows continued growth in advanced therapy clinical trials in the UK for 2025
The number of ongoing advanced therapy clinical trials in the UK reached 193 in 2025, with 56% being early-stage trials, and 80% being commercially sponsored. The data is presented today in the Cell and Gene Therapy Catapult’s (CGT Catapult) UK 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.
In an increasingly competitive global market, the UK continues to hold a strong position in clinical research, participating in 9% of all global trials and 57% of all European trials in 2025.
Similar to 2024, the majority, over 80%, of ATMP clinical trials in 2025 were in gene therapies, with an even split between ex vivo and in vivo. Oncology continues to dominate, with 35% of trials in this area, and there is promising growth in other disease areas such as inflammation and the immune system.
Matthew Durdy, Chief Executive of the CGT Catapult, said:
With a supportive regulator and recent updates such as the increase to the NICE thresholds, the UK is well-positioned to benefit from the health and economic benefits of advanced therapy clinical trials. These trials are vital to ensuring the healthcare system is ready to adopt innovative therapies more widely, as they help build the skills, infrastructure, and clinical environment needed to deliver these therapies safely and efficiently.
